A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells

• DOI: 10.2217/imt-2021-0143
• Publication Date: 2022-02-14T09:54:06Z
• Authors: Xi Zhang; Wei Xia Ang; Zhicheng Du; Yu Yang Ng; Shijun Zha; Can Chen; Lin Xiao; Jia Yi Ng; Wee Joo Chng; Shu Wang
• Keywords: 0301 basic medicine; 0303 health sciences; Receptors, Chimeric Antigen; T-Lymphocytes; Interleukin-3 Receptor alpha Subunit; Mice, SCID; Immunotherapy, Adoptive; Xenograft Model Antitumor Assays; 3. Good health; Leukemia, Myeloid, Acute; Mice; 03 medical and health sciences; Mice, Inbred NOD; Cell Line, Tumor; Animals; Humans

Aim: To investigate whether anti-CD123 chimeric antigen receptor (CAR)-expressing Vγ9Vδ2 T cells could be an alternative for acute myeloid leukemia (AML) treatment. Materials & methods:Ex vivo expanded were electroporated with CAR-encoding mRNA. The effector function and specificity of the modified examined by in vitro cytotoxicity, degranulation cytokine release level. was analyzed using xenograft KG1-luc model NOD-SCID-γc-/- mice. Results: exhibited significantly improved activities against both AML cell lines primary vitro. In mouse model, displayed enhanced tumor control potency. Conclusion: Anti-CD123 CAR-expressing may serve as way to target AML.